Boehringer Ingelheim GMBH and Eli Lilly & Co. will promote the first-of-its-kind cardiovascular mortality risk reduction claim for their type 2 diabetes drug Jardiance (empagliflozin) with a combination of unbranded and branded consumer awareness campaigns and professional detailing to cardiologists.
On Dec. 2, the US FDA approved Jardiance, an SGLT-2 inhibitor, to reduce the risk of cardiovascular death in adults...






